Document is current

Any future updates will be listed below

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

Crossref DOI link: https://doi.org/10.1038/s41416-021-01403-z

Published Online: 2021-06-02

Published Print: 2021-08-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark